Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179737 | 0.83 | TSHR (0.34) | KDM4E | |
| SCHEMBL12920256 | 0.80 | SHBG (0.38) | KDM4ESHBG | |
| SCHEMBL3188361 | 0.79 | KDM4E (0.39) | KDM4ESHBG | |
| SCHEMBL3185501 | 0.78 | KDM4E (0.36) | KDM4ESHBG | |
| SCHEMBL3185516 | 0.78 | CTSV (0.40) | KDM4E | |
| SCHEMBL29013702 | 0.76 | — | — | |
| Ethylene Glycol SCHEMBL27905367 | 0.75 | KDM4E (0.33) | KDM4ESHBG | |
| SCHEMBL3172425 | 0.74 | KDM4E (0.31) | KDM4E | |
| SCHEMBL18483727 | 0.72 | MEN1 (0.34) | — | |
| Propylene Glycol SCHEMBL27888459 | 0.72 | TDP1 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | claimed |
| WO-2008004788-A1 | NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF | WONKISOPHARM CO., LTD. (KR) | 2008-01-10 | — | — | WO | claimed |
| CN-106309421-B | Pharmaceutical composition and cosmetic composition | 沃凯索法株式会社 | 2020-08-25 | — | — | CN | disclosed |
| US-8420853-B2 | Derivatives of cyclic compound and the use thereof | Wonkisopharm Co., Ltd (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | WONKISOPHARM CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022461-A1 | Novel Derivatives of Cyclic Compound And The Use Thereof | TYR, MC1R, PDE7A | KDM4E 1668/4885SHBG 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.